Immunomodulation in presymptomatic type 1 diabetes: The Teplizumab breakthrough
Type 1 diabetes is a progressive autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. Stage 2 T1D represents a critical asymptomatic window defined by the presence of two or more islet autoantibodies and dysglycemia, carrying an active, near-inevitable risk of progression to i...